BriaCell Therapeutics completed a best-efforts public offering of 5,366,726 units, generating approximately $30 million in gross proceeds before fees and expenses. Each unit consists of one common share (or a pre-funded warrant in lieu thereof) and one warrant, both of which will trade separately on the Nasdaq Capital Market under the symbol “BCTXL” beginning January 14, 2026. The warrants are immediately exercisable, entitling holders to one common share at a predetermined exercise price and will remain valid for five years. The offering is expected to close on January 15, 2026, subject to customary closing conditions, and was led by ThinkEquity as sole placement agent.

BriaCell intends to allocate the net proceeds toward working capital, general corporate purposes, and the advancement of its clinical-stage immunotherapy programs. This infusion of liquidity is timed to support ongoing trial enrollment, manufacturing scale-up for its lead candidates, and regulatory preparation activities. Management has indicated that the additional capital will also fund combination studies designed to enhance Bria-OTS’s efficacy profile in metastatic breast cancer and other solid tumor indications.

In its Phase 1/2a Bria-OTS study for metastatic breast cancer, BriaCell reported an 11-month sustained complete resolution of a lung metastasis in a 78-year-old patient with hormone receptor-positive, HER2-negative disease. The patient achieved 100% tumor clearance after four doses of Bria-OTS monotherapy, with no treatment-limiting toxicities and stable disease at all other evaluable sites. The dose-escalation portion of the trial is now complete, and the study has entered its Phase 2a expansion, which evaluates Bria-OTS in combination with an immune checkpoint inhibitor.

BriaCell is preparing to report interim combination-cohort data from the Bria-OTS Phase 2a expansion in the second half of 2026. Concurrently, the company plans to file updated clinical and manufacturing documentation with regulatory authorities to support future registrational trials. Investors will be watching closely for proof-of-concept results in combination regimens, as well as any updates on patient enrollment rates and safety data, which could meaningfully de-risk the program and enhance the company’s valuation profile.